Beta Bionics (BBNX) Piper Sandler 37th Annual Healthcare Conference summary

Market adoption and patient outcomes

• Achieved strong Q3 results with high adoption rates, especially among MDI patients, nearing competitors’ levels.

• Sales force is smaller but highly productive, with significant penetration in accessible clinics.

• Product resonates due to simplicity and strong clinical outcomes with minimal patient effort.

• Patient base reflects the broader type 1 diabetes population, with a slight skew toward higher A1c due to fewer options for those patients.

• About 70% of patients come from MDI, with over 25% from type 2 diabetes, despite no formal indication for type 2.

Clinical performance and competitive differentiation

• Real-world data shows a median A1c drop from 9.7% to 7.5% in patients who rarely bolus.

• Approximately 50% of users achieve A1c under 7%, with bi-hormonal systems showing up to 92% under 7% in early data.

• One-third of new patients are competitive conversions, with algorithm performance cited as a key differentiator.

• The algorithm’s ability to deliver rapid, frequent corrections is highlighted as a unique advantage.

Channel strategy and financial dynamics

• Pharmacy channel saw significant growth in Q3, nearly doubling patient numbers compared to Q2.

• No pricing degradation in pharmacy; Q3 pricing dip attributed to inventory destocking.

• Pharmacy channel expected to provide a strong tailwind as patient base grows, with profitability improving as scale increases.

• Deliberate approach to sales force expansion, prioritizing experienced hires for a complex, category-creating sale.